Cite
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after a new induction regimen in intermediate and high-risk follicular lymphoma patients according to the follicular lymphoma international prognostic index (FLIPI): A multicenter, prospective Phase II trial of Spanish Lymphoma Oncology Group
MLA
Ruth Álvarez Cabellos, et al. “Consolidation Treatment with Yttrium-90 Ibritumomab Tiuxetan after a New Induction Regimen in Intermediate and High-Risk Follicular Lymphoma Patients According to the Follicular Lymphoma International Prognostic Index (FLIPI): A Multicenter, Prospective Phase II Trial of Spanish Lymphoma Oncology Group.” Leukemia & Lymphoma, Apr. 2013, pp. 1–16. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........884b173211146841c681baef056acd00&authtype=sso&custid=ns315887.
APA
Ruth Álvarez Cabellos, Francisco R García-Arroyo, Cristina Quero Blanco, Miguel Cruz, Antonio García Sánchez, Antonio Rueda, Josep Gumà-Padrò, José Gómez-Codina, Mariano Provencio, Marta Llanos, Juan Ramón Delgado Pérez, & Luis de la Cruz. (2013). Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after a new induction regimen in intermediate and high-risk follicular lymphoma patients according to the follicular lymphoma international prognostic index (FLIPI): A multicenter, prospective Phase II trial of Spanish Lymphoma Oncology Group. Leukemia & Lymphoma, 1–16.
Chicago
Ruth Álvarez Cabellos, Francisco R García-Arroyo, Cristina Quero Blanco, Miguel Cruz, Antonio García Sánchez, Antonio Rueda, Josep Gumà-Padrò, et al. 2013. “Consolidation Treatment with Yttrium-90 Ibritumomab Tiuxetan after a New Induction Regimen in Intermediate and High-Risk Follicular Lymphoma Patients According to the Follicular Lymphoma International Prognostic Index (FLIPI): A Multicenter, Prospective Phase II Trial of Spanish Lymphoma Oncology Group.” Leukemia & Lymphoma, April, 1–16. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........884b173211146841c681baef056acd00&authtype=sso&custid=ns315887.